TERN
Terns Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.95
−0.03%Price chart
Apr 9Apr 14Apr 17Apr 22Apr 27Apr 30May 5May 15
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−46.3x
Market Cap
$6.12B
MomentumView details →
1D Return
−0.03%
YTD Return
+31.06%
RSI (14)
73.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−46.3x
Market Cap
$6.12B
RSI (14)
73.9
MomentumView details →
1D Return
−0.03%
YTD Return
+31.06%
SummaryUpdated Dec 1, 2025
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Foster City, California. The company went public in February 2021 and focuses on developing innovative small-molecule therapies for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and obesity. As a clinical-stage company, Terns has no approved products on the market and is currently advancing multiple drug candidates through various phases of clinical trials.
Similar companies
Latest newsMore news →
Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.19d agoMerck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.31d agoMerck acquired Terns Pharmaceuticals and Cidara Therapeutics to broaden its oncology and virology portfolios.35d ago